Sedentary behavior and prostate cancer risk in the NIH-AARP Diet and Health Study.
Lynch BM, Friedenreich CM, Kopciuk KA, Hollenbeck AR, Moore SC, Matthews CE.
Cancer Epidemiol Biomark Prev Publ. 2014 Feb 13;
BPH / Prostatitis / PIN
A Pooled Analysis of Individual Patient Data from Registrational Trials of Silodosin in the Treatment of Non-neurogenic Male Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Enlargement.
Novara G, Chapple CR, Montorsi F.
BJU Int. 2014 Feb 27
Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea.
Takeda M, Yokoyama O, Lee SW, Murakami M, Morisaki Y, Viktrup L.
Int J Urol Off J Jpn Urol Assoc. 2014 Feb 27;
Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era.
Zu K, Mucci L, Rosner BA, Clinton SK, Loda M, Stampfer MJ, et al.
J Natl Cancer Inst. 2014 Feb 1;106(2).
Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners.
Ploussard G, Nicolaiew N, Mongiat-Artus P, Terry S, Allory Y, Vacherot F, et al.
Prostate Cancer Prostatic Dis. 2014 Feb 11;
The roles of multiparametric MRI, PCA3, and PHI: which is the best predictor of prostate cancer after a negative biopsy? Results of a prospective study.
Porpiglia F, Russo F, Manfredi M, Mele F, Fiori C, Bollito E, et al.
J Urol. 2014 Feb 8;
Comparison of 8, 10, 12, 16, 20 cores prostate biopsies in the determination of prostate cancer and the importance of prostate volume.
Ceylan C, Doluoglu OG, Aglamis E, Baytok O.
Can Urol Assoc J J Assoc Urol Can. 2014 Feb (1-2):E81-5.
Diet / supplements / herbal medicine
Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.
Mariani S, Lionetto L, Cavallari M, Tubaro A, Rasio D, De Nunzio C, et al.
Int J Mol Sci. 2013;15(1):1433–40.
Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.
Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C, Jugurnauth-Little S, et al.
Br J Cancer [Internet]. 2014 Feb 20
First round of targeted biopsies with magnetic resonance imaging/ultrasound-fusion images compared to conventional ultrasound-guided trans-rectal biopsies for the diagnosis of localised prostate cancer.
Mozer P, Rouprêt M, Le Cossec C, Granger B, Comperat E, de Gorski A, et al.
BJU Int. 2014 Feb 19
Quality of Life
Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer.
Kim SP, Gross CP, Nguyen PY, Smaldone MC, Thompson RH, Shah ND, et al.
Prostate Cancer Prostatic Dis. 2014 Feb 25;
Prostate Cancer and Quality of Life: Analysis of Response Shift Using Triangulation Between Methods.
Serdà I Ferrer B-C, Del Valle A, Marcos-Gragera R.
J Gerontol Nurs. 2014 Feb 19;1–10.
Validation and reliability of a smartphone application for the international prostate symptom score questionnaire: a randomized repeated measures crossover study.
Kim JH, Kwon S-S, Shim SR, Sun HY, Ko YM, Chun D-I, et al.
J Med Internet Res. 2014;16(2):e38.
Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy.
Hansen J, Gandaglia G, Bianchi M, Sun M, Rink M, Tian Z, et al.
Can Urol Assoc J J Assoc Urol Can. 2014 Jan;8(1-2):E75–80.
Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence.
Izard JP, True LD, May P, Ellis WJ, Lange PH, Dalkin B, et al.
Am J Surg Pathol. 2014 Mar;38(3):333–8.
Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study.
Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S, et al.
Eur Urol epub ahead of print.
Does family history of prostate cancer affect outcomes following radiotherapy?
Bagshaw H, Ruth K, Horwitz EM, Chen DYT, Buyyounouski MK.
Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014 Feb 20;
Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort
Bhindi B, Locke J, Alibhai SMH, Kulkarni GS, Margel DS, Hamilton RJ, et al.
Eur Urol. 2014 Feb 14;
Alcohol Intake Increases High-grade Prostate Cancer Risk Among Men Taking Dutasteride in the REDUCE Trial.
Fowke JH, Howard L, Andriole GL, Freedland SJ.
Eur Urol. 2014 Feb 9;
Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
Poulsen MH, Frost M, Abrahamsen B, Brixen K, Walter S.
Scand J Urol. 2014 Feb 19;
Measuring Individual Burden of Illness for Depression among prostate cancer patients.
Sharpley CF, Bitsika V, Christie DRH.
Psychooncology. 2014 Feb 14;
Factors associated with the survival of prostate cancer patients with rectal involvement.
Wang H, Yao Y, Li B.
Diagn Pathol. 2014;9(1):35.
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, et al.
Lancet Oncol. epub ahead of print.
Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes.
Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, et al.
BMJ. 2014 Feb 26;348.
Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
Bhattasali O, Chen LN, Woo J, Park J-W, Kim JS, Moures R, et al.
Radiat Oncol Lond Engl. 2014;9:52.
Intensity-Modulated Radiation Therapy Leads to Survival Benefit Only in Patients with High-Risk Prostate Cancer: a Population-Based Study.
Gandaglia G, Karakiewicz PI, Briganti A, Trinh Q, Schiffmann J, Tian Z, et al.
Ann Oncol Off J Eur Soc Med Oncol ESMO. 2014 Feb 22;
A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.
Lee D, Porter J, Gladwell D, Brereton N, Nielsen SK.
J Med Econ. 2014 Feb 25;
Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy.
Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Hamstra DA.
Am J Clin Oncol. 2014 Feb 10;
Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years.
Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, et al.
Eur Urol. 2014 Feb 18;